6287 related articles for article (PubMed ID: 2573651)
1. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
Cole S; Stratford IJ; Adams GE
Int J Radiat Biol; 1989 Nov; 56(5):587-91. PubMed ID: 2573651
[No Abstract] [Full Text] [Related]
2. Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069.
Cole S; Robbins L
Radiother Oncol; 1989 Nov; 16(3):235-43. PubMed ID: 2587812
[TBL] [Abstract][Full Text] [Related]
3. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
Cole S; Stratford IJ; Fielden EM; Adams GE; Leopold W; Elliott W; Suto M; Sebolt-Leopold J
Int J Radiat Oncol Biol Phys; 1992; 22(3):545-8. PubMed ID: 1735694
[TBL] [Abstract][Full Text] [Related]
4. Bioreductive drugs and the selective induction of tumour hypoxia.
Bremner JC; Stratford IJ; Bowler J; Adams GE
Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
[TBL] [Abstract][Full Text] [Related]
5. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
Stratford IJ; Adams GE; Godden J; Howells N
Int J Radiat Biol; 1989 Mar; 55(3):411-22. PubMed ID: 2564037
[TBL] [Abstract][Full Text] [Related]
6. Broad-shouldered survival curves of a human melanoma xenograft. Implications for radiation therapy in the absence and presence of misonidazole.
Rofstad EK; Brustad T
Acta Radiol Oncol; 1981; 20(4):261-5. PubMed ID: 6277155
[TBL] [Abstract][Full Text] [Related]
7. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
Chaplin DJ
Radiat Res; 1988 Aug; 115(2):292-302. PubMed ID: 3406369
[TBL] [Abstract][Full Text] [Related]
8. Radiation response of the cells of a human malignant melanoma xenograft. Effect of hypoxic cell radiosensitizers.
Rofstad EK
Radiat Res; 1981 Sep; 87(3):670-83. PubMed ID: 7280191
[No Abstract] [Full Text] [Related]
9. Radiosensitizing effects of misonidazole and SR 2508 on a human melanoma transplanted in nude mice: influence on repair of potentially lethal damage.
Guichard M; Malaise EP
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):465-8. PubMed ID: 6213589
[TBL] [Abstract][Full Text] [Related]
10. Bioreductive drugs in cancer therapy.
Stratford IJ
BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
[No Abstract] [Full Text] [Related]
11. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
Chaplin DJ; Acker B
Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):579-85. PubMed ID: 3558048
[TBL] [Abstract][Full Text] [Related]
12. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
[TBL] [Abstract][Full Text] [Related]
13. Hypobaric hypoxia: a method for testing bioreductive drugs in vivo.
McAleer JJ; McKeown SR; MacManus MP; Lappin TR; Bridges JM
Int J Radiat Oncol Biol Phys; 1992; 23(3):551-5. PubMed ID: 1612955
[TBL] [Abstract][Full Text] [Related]
14. Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs.
Adams GE; Stratford IJ; Bremner JC; Edwards HS; Fielden EM
Radiother Oncol; 1991; 20 Suppl 1():85-91. PubMed ID: 2020774
[No Abstract] [Full Text] [Related]
15. Partial hypoxia as a cause of radioresistance in a human tumor xenograft: its influence illustrated by the sensitizing effect of misonidazole and hyperbaric oxygen.
Reynaud-Bougnoux A; Lespinasse F; Malaise EP; Guichard M
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1283-6. PubMed ID: 3759547
[TBL] [Abstract][Full Text] [Related]
16. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.
Chaplin DJ; Durand RE; Stratford IJ; Jenkins TC
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1091-5. PubMed ID: 3755714
[TBL] [Abstract][Full Text] [Related]
17. The experimental development of bioreductive drugs and their role in cancer therapy.
Workman P; Stratford IJ
Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
[TBL] [Abstract][Full Text] [Related]
18. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.
Ahmed I; Jenkins TC; Walling JM; Stratford IJ; Sheldon PW; Adams GE; Fielden EM
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1079-81. PubMed ID: 3755711
[TBL] [Abstract][Full Text] [Related]
19. The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay.
Horsman MR; Overgaard J; Chaplin DJ
Acta Oncol; 1988; 27(6b):861-2. PubMed ID: 3233175
[No Abstract] [Full Text] [Related]
20. Bioreductive therapy.
Chaplin DJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
[No Abstract] [Full Text] [Related]
[Next] [New Search]
